Home » Blog » Biolase Expands Intellectual Property Portfolio With New United States and Foreign Patents

Biolase Expands Intellectual Property Portfolio With New United States and Foreign Patents


Firm continues to guide the dental laser {industry} with 302 issued and 31 pending patents

LAKE FOREST, Calif., July 25, 2022 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the worldwide chief in dental lasers, introduced as we speak that the corporate has obtained 5 new United States patents and 7 new overseas patents within the final 12 months.

In June, the corporate obtained discover from the Korean Mental Property Workplace of the Determination to Grant, “KR #2412063 titled Pre-Initiated Optical Fibers for Medical Purposes,” an necessary addition to BIOLASE’s Korean IP portfolio. Additionally, the Canadian Mental Property Workplace (CIPO) granted, #2,935,691 titled Twin Wavelength Laser Therapy System.

Two extra latest patents are US #11,250,941 titled Dental Laser Interface System and Technique issued on Feb. 15, 2022, issued within the U.S. and BR112015008998-4, Handpiece Meeting for Laser Therapy System issued in Brazil on Feb. 8, 2022.

BIOLASE maintains an industry-leading portfolio of mental property (“IP”) with 302 issued and 31 pending purposes.

“BIOLASE’s proprietary laser merchandise signify a long time of modern analysis and incorporate many patented and patent-pending applied sciences particularly designed and examined to offer biologically and clinically superior efficiency with a extra snug affected person expertise and quicker restoration occasions,” commented BIOLASE Vice President of Innovation and Enterprise Growth, William Brown, Jr.

“The brand new patents are all associated to the flagship Waterlase laser methods and market-leading Epic diode applied sciences, and increase the safety of BIOLASE’s key IP nicely into the longer term,” stated John Beaver, President and Chief Government Officer of BIOLASE.

About BIOLASE

BIOLASE is a medical gadget firm that develops, manufactures, markets, and sells laser methods in dentistry and drugs. BIOLASE’s merchandise advance the observe of dentistry and drugs for sufferers and healthcare professionals. BIOLASE’s modern merchandise present cutting-edge expertise at aggressive costs to ship superior outcomes for dentists and sufferers. BIOLASE’s principal merchandise are revolutionary dental laser methods that carry out a broad vary of dental procedures, together with beauty and complicated surgical purposes. BIOLASE has offered over 43,300 laser methods up to now in over 80 nations around the globe. Laser merchandise underneath improvement handle BIOLASE’s core dental market and different adjoining medical and shopper purposes.

For updates and knowledge on Waterlase iPlus®, Waterlase Categorical™, and laser dentistry, discover BIOLASE on-line at www.biolase.com, Fb at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered logos of BIOLASE, Inc.

Cautionary Assertion Relating to Ahead-Wanting Statements

This press launch incorporates forward-looking statements, as that time period is outlined within the Non-public Litigation Reform Act of 1995, that contain vital dangers and uncertainties. Ahead-looking statements will be recognized via the usage of phrases equivalent to could,” “may,” “will,” “intend,” “ought to,” “may,” “can,” “would,” “proceed,” “count on,” “consider,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “search,” and related expressions and variations or the negatives of those phrases or different comparable terminology. Readers are cautioned to not place undue reliance on these forward-looking statements, which mirror BIOLASE’s present expectations and communicate solely as of the date of this launch. Precise outcomes could differ materially from BIOLASE’s present expectations relying upon various elements. These elements embody, amongst others, these dangers and uncertainties which can be described within the “Threat Components” part of BIOLASE’s annual report filed on Kind 10-Okay filed with the Securities and Alternate Fee. Besides as required by legislation, BIOLASE doesn’t undertake any duty to revise or replace any forward-looking statements.

For additional info, please contact:

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com

Cision View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/biolase-expands-intellectual-property-portfolio-with-new-united-states-and-foreign-patents-301592167.html

SOURCE BIOLASE, Inc.

Firm Codes: NASDAQ-SMALL:BIOL





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *